Share Twitter LinkedIn Facebook Email Joan Schiller, MD, shares Keynote 189 and whether the data impacts her view of PDL-1 expression and patient selection at the 2018 Annual Meeting.
VIDEO: iTeos and GSK’s TIGIT Combination Therapy Shows Significant Promise at ESMO 2024 Non-Small Cell Lung Cancer 2 Mins Read
VIDEO: FDA Approves Atezolizumab / Tecentriq Hybreza For Subcutaneous PD-(L)1 Cancer Immunotherapy in NSCLC Kidney 4 Mins Read